Dr. Jan-Willem van der Laan is senior staff member (SOR-RIVM) at the Division of Drug Discovery & Safety.

More information about Jan van der Laan

van der Laan, Jan Willem, PhD

In 1980 Jan Willem van der Laan joined the National Institute for Public Health and the Environment (RIVM, Bilthoven) as a biochemist and pharmacologist on CNS targets. In 1990 he became assessor Pharmacology and Toxicology of Human Pharmaceuticals at the same institute. Since 2011 he serves in the same role the Medicines Evaluation Board, located in Utrecht, the Netherlands. He is chair of the EMA/CHMP Safety Working Party since 2012. His contributions to the International Council on Harmonization started in 1993 on Carcinogenicity Testing. In 2012 the discussions on this topic have been restarted to reduce the number of 2-yr studies in rodents, and Jan Willem is Regulatory Chair on this process.

Jan Willem van der Laan is leading a project on “Mechanistic differentiation of nongenotoxic carcinogenic pharmaceuticals and their human relevance”, funded by the Medicines Evaluation Board, on which project Britt Duijndam is working as a Ph.D student.

Projects

• Pro-mitogenic effects of insulin analogues and mammary gland tumor development

Courses

• Caput: "Regulation of Drug Safety (RDS)"

Publications